Cargando…
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?
PURPOSE: We aimed to determine the COVID-19 infection rate and determine the factors that affect hospitalization and prognosis in patients receiving systemic chemotherapy (CT), immunotherapy (IT) and molecular-targeted therapies at our hospital within three months after the onset of COVID-19 pandemi...
Autores principales: | Ayhan, Murat, Laçin, Şahin, Özyükseler, Deniz T, Sürmeli, Heves, Doğan, Akif, Turan, Merve, odabas, Hatice, Turan, Nedim, Yıldırım, Mahmut Emre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107490/ https://www.ncbi.nlm.nih.gov/pubmed/33961521 http://dx.doi.org/10.1177/10781552211015762 |
Ejemplares similares
-
Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023) -
Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020) -
What have we learned in interventional pulmonology in the past decade?
por: ÖZGÜL, Mehmet Akif, et al.
Publicado: (2019) -
Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer
por: Cihan, Sener, et al.
Publicado: (2015) -
Comparison of Biparametric and Multiparametric Prostate Magnetic Resonance Imaging in Predicting Oncologic Outcomes After Radical Prostatectomy
por: EFILOGLU, Ozgur, et al.
Publicado: (2022)